SOPHIA ANTIPOLIS, France—Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced July 5 that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were made to certain rights under non-financial clauses of the agreement.

Nicox remains eligible to receive the same sales milestones of up to $17.2 million together with tiered royalties of between 5 percent and 9 percent of net sales of Zerviate by Ocumension. Zerviate is currently being evaluated in a confirmatory Phase 3 clinical trial in China by Ocumension, to support a Chinese New Drug Application for the treatment of ocular itching associated with allergic conjunctivitis.